Literature DB >> 28637402

Antioxidant SkQ1 Alleviates Signs of Alzheimer's Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration.

Nataliya G Kolosova1, Mikhail A Tyumentsev2, Natalia A Muraleva2, Elena Kiseleva2, Anton O Vitovtov2, Natalia A Stefanova1.   

Abstract

BACKGROUND: Mitochondrial dysfunction is called the missing link between brain aging and Alzheimer's disease (AD), the most common type of age-related dementia worldwide. Among the most advanced and promising of approaches to prevention or slowing of AD are therapeutic strategies targeting mitochondria.
OBJECTIVE: Mitochondria-targeted antioxidant SkQ1 can suppress the development of AD signs, but its therapeutic potential in AD at clinical stages is currently unknown.
METHOD: Using OXYS rats that simulate key characteristics of sporadic AD, we evaluated effects of SkQ1 treatment from the age of 19 to 24 months on the locomotor and exploratory activities, signs of neurodegeneration detectable by magnetic resonance imaging (MRI), amyloid-β (Aβ) protein levels in the hippocampus and serum, and structure of the mitochondrial apparatus in hippocampal neurons.
RESULTS: Treatment with SkQ1 increased behavioral activity in OXYS and Wistar (control) rats. According to MRI, SkQ1 decreased the percentage of animals with demyelination only among Wistar rats. At the same time, the antioxidant reduced hippocampal Аβ1-40 and Аβ1-42 protein levels in both rat strains and did not affect serum Аβ levels. The number of mitochondria was significantly lower in OXYS rats; SkQ1 had no effect on this parameter but significantly reduced the destructive changes in mitochondria of both rat strains. As a result, in OXYS rats, the proportion of severely damaged mitochondria decreased, whereas in Wistar rats, the proportion of intact mitochondria increased.
CONCLUSION: According to our past and present results, the repair of the mitochondrial apparatus by SkQ1 is a promising strategy against AD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer's disease; Aβ; OXYS rats.; SkQ1; mitochondria; neurodegeneration

Mesh:

Substances:

Year:  2017        PMID: 28637402     DOI: 10.2174/1567205014666170621111033

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  11 in total

Review 1.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 2.  Interactions between Amyloid-Β Proteins and Human Brain Pericytes: Implications for the Pathobiology of Alzheimer's Disease.

Authors:  Donald J Alcendor
Journal:  J Clin Med       Date:  2020-05-15       Impact factor: 4.241

Review 3.  What Is Nuclear Factor Kappa B (NF-κB) Doing in and to the Mitochondrion?

Authors:  Benedict C Albensi
Journal:  Front Cell Dev Biol       Date:  2019-08-07

4.  Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1: A Transcriptome Profiling Study.

Authors:  Natalia A Stefanova; Nikita I Ershov; Nataliya G Kolosova
Journal:  Oxid Med Cell Longev       Date:  2019-07-15       Impact factor: 6.543

Review 5.  Coenzyme Q10 Analogues: Benefits and Challenges for Therapeutics.

Authors:  Juan M Suárez-Rivero; Carmen J Pastor-Maldonado; Suleva Povea-Cabello; Mónica Álvarez-Córdoba; Irene Villalón-García; Manuel Munuera-Cabeza; Alejandra Suárez-Carrillo; Marta Talaverón-Rey; José A Sánchez-Alcázar
Journal:  Antioxidants (Basel)       Date:  2021-02-04

Review 6.  Disentangling Mitochondria in Alzheimer's Disease.

Authors:  Ashu Johri
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

Review 7.  Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update.

Authors:  Giovanna Cenini; Wolfgang Voos
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

Review 8.  Prevention of Cognitive Decline in Alzheimer's Disease by Novel Antioxidative Supplements.

Authors:  Koh Tadokoro; Yasuyuki Ohta; Haruhiko Inufusa; Alan Foo Nyuk Loon; Koji Abe
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

9.  SkQ1 Suppresses the p38 MAPK Signaling Pathway Involved in Alzheimer's Disease-Like Pathology in OXYS Rats.

Authors:  Natalia A Muraleva; Natalia A Stefanova; Nataliya G Kolosova
Journal:  Antioxidants (Basel)       Date:  2020-07-28

10.  MEK1/2-ERK Pathway Alterations as a Therapeutic Target in Sporadic Alzheimer's Disease: A Study in Senescence-Accelerated OXYS Rats.

Authors:  Natalia A Muraleva; Nataliya G Kolosova; Natalia A Stefanova
Journal:  Antioxidants (Basel)       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.